# A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

> **NCT06653842** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Palvella Therapeutics, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Cutaneous Venous Malformations

## Interventions

- **DRUG:** QTORIN 3.9% rapamycin anhydrous gel

## Key facts

- **NCT ID:** NCT06653842
- **Lead sponsor:** Palvella Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-03
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06653842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06653842, "A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06653842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*